journal article·2021

All-purpose nanostrategy based on dose deposition enhancement, cell cycle arrest, DNA damage, and ROS production as prostate cancer radiosensitizer for potential clinical translation

Xiao-xiao Guo, Zhen-hu Guo, Jing-song Lu, Wen-sheng Xie, Qiu-zi Zhong, Xiao-dan Sun, Xiu-mei Wang, Jian-ye Wang, Ming Liu, Ling-yun Zhao

Nanoscale· Volume 13· Issue 34
Publisher page

Abstract

Radiotherapy (RT) is one of the main treatments for men with prostate cancer (PCa). To date, numerous sophisticated nano-formulations as radiosensitizers have been synthesized with inspiring therapeutic effects both in vitro and in vivo; however, almost all the attention has been paid on the enhanced dose deposition effect by secondary electrons of nanomaterials with high atomic numbers (Z); despite this, cell-cycle arrest, DNA damage, and also reactive oxygen species (ROS) production are critical working mechanisms that account for radiosensitization. Herein, an 'all-purpose' nanostrategy based on dose deposition enhancement, cell cycle arrest, and ROS production as prostate cancer radiosensitizer for potential clinical translation was proposed. The rather simple structure of docetaxel-loaded Au nanoparticles (NPs) with prostate specific membrane antigen (PSMA) ligand conjugation have been successfully synthesized. Enhanced cellular uptake achieved via the selective internalization of the NPs by PCa cells with positive PSMA expression could guarantee enhanced dose deposition. Moreover, the as-synthesized nanosystem could effectively arrest the cell cycle at G2/M phases, which would reduce the ability of DNA damage repair for more irradiation sensitive of the PCa cells. Moreover, the G2/M phase arrest would further promote cascade retention and the enrichment of NPs within the cells. Furthermore, ROS generation and double strand breaks greatly promoted by NPs under irradiation (IR) could also provide an underlying basis for effective radiosensitizers. In vitro and in vivo investigations confirmed the as-synthesized NPs as an effective nano-radiosensitizer with ideal safety. More importantly, all moieties within the present nanosystem have been approved by FDA for the purpose of PCa treatment, thus making it highly attractive for clinical translation.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Radiation Therapy and Dosimetry · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Urology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, 100730, China

Graduate School of Peking Union Medical College, Beijing, 100730, China

Key Laboratory of Advanced Materials, Ministry of Education of China, School of Materials Science and Engineering, Tsinghua University, Beijing, 100084, China

Department of Radiotherapy, National Center of Gerontology, Institute of Geriatric Medicine, Beijing Hospital, Chinese Academy of Medical Science, Beijing, 100730, China

Funding

National Natural Science Foundation of China

References (53)

Show source-provided references
1. Rawla · World J. Oncol. · 2019 · 10 · 6310.14740/wjon1191 ↗
2. Forouzanfar · Lancet · 2016 · 388 · 165910.1016/S0140-6736(16)31679-8 ↗
3. Haglind · Eur. Urol. · 2015 · 68 · 21610.1016/j.eururo.2015.02.029 ↗
4. Oake · J. Urol. · 202010.1097/ju.0000000000000805 ↗
5. Cornford · Eur. Urol. · 2021 · 79 · 26310.1016/j.eururo.2020.09.046 ↗
6. Xiaoxiao · Int. J. Clin. Oncol. · 2019 · 24 · 95710.1007/s10147-019-01427-9 ↗
7. Voorwerk · Nat. Med. · 2019 · 25 · 92010.1038/s41591-019-0432-4 ↗
8. Pujade-Lauraine · Future Oncol. · 2018 · 14 · 210310.2217/fon-2018-0070 ↗
9. Wei · J. Nanobiotechnol. · 2021 · 19 · 15510.1186/s12951-021-00875-8 ↗
10. Bai · J. Nanobiotechnol. · 2020 · 18 · 13110.1186/s12951-020-00678-3 ↗
11. Zhang · J. Controlled Release · 2020 · 326 · 13110.1016/j.jconrel.2020.06.015 ↗
12. Xie · Adv. Mater. · 2019 · 31 · e180224410.1002/adma.201802244 ↗
13. Potier · J. Med. Chem. · 1991 · 3 · 992
14. Terasima · Biophys. J. · 1963 · 3 · 1110.1016/S0006-3495(63)86801-0 ↗
15. Sinclair · Radiat. Res. · 1966 · 29 · 45010.2307/3572025 ↗
16. Kim · Nat. Nanotechnol. · 2012 · 7 · 6210.1038/nnano.2011.191 ↗
17. Rastinehad · Proc. Natl. Acad. Sci. U. S. A. · 2019 · 116 · 1859010.1073/pnas.1906929116 ↗
18. Gardner · AACR · 2013 · Abstract LB-90
19. Ju · ACS Nano · 2017 · 11 · 923910.1021/acsnano.7b04461 ↗
20. Lv · Mol. Pharm. · 2018 · 15 · 184210.1021/acs.molpharmaceut.8b00026 ↗
21. Roy · J. Med. Chem. · 2015 · 58 · 309410.1021/jm5018384 ↗
22. Zhang · Biomaterials · 2012 · 33 · 640810.1016/j.biomaterials.2012.05.047 ↗
23. Ma · ACS Appl. Mater. Interfaces · 2017 · 9 · 1303710.1021/acsami.7b01112 ↗
24. Zhang · Adv. Sci. · 2019 · 6 · 180180610.1002/advs.201801806 ↗
25. Luo · Small · 2019 · 15 · e190096810.1002/smll.201900968 ↗
26. Butterworth · Nanoscale · 2012 · 4 · 483010.1039/c2nr31227a ↗
27. Gholami · Sci. Rep. · 2019 · 9 · 1434610.1038/s41598-019-50861-2 ↗
28. Zhang · Int. J. Nanomed. · 2011 · 6 · 207110.2147/IJN.S21657 ↗
29. Roy · J. Med. Chem. · 2015 · 58 · 309410.1021/jm5018384 ↗
30. François · ChemMedChem · 2011 · 6 · 200310.1002/cmdc.201100311 ↗
31. Sindhwani · Nat. Mater. · 2020 · 19 · 56610.1038/s41563-019-0566-2 ↗
32. O'Neill · Mol. Cancer · 2011 · 10 · 12610.1186/1476-4598-10-126 ↗
33. Mukherjee · ChemMedChem · 2014 · 9 · 135610.1002/cmdc.201300549 ↗
34. Sahai · Nat. Rev. Cancer · 2020 · 20 · 17410.1038/s41568-019-0238-1 ↗
35. Fard · Appl. Cancer Res. · 2017 · 37 · 2910.1186/s41241-017-0035-7 ↗
36. Inhestern · Ann. Oncol. · 2017 · 28 · 191710.1093/annonc/mdx202 ↗
37. Bannister · Br. J. Radiol. · 2020 · 93 · 2019074210.1259/bjr.20190742 ↗
38. Bromma · Cancer Nanotechnol. · 2020 · 11 · 810.1186/s12645-020-00064-6 ↗
39. Shi · Smart Mater. Struct. · 2020 · 1 · 32
40. Zs · Chin. Chem. Lett. · 2020 · 31 · 134510.1016/j.cclet.2020.03.001 ↗
41. Orthwein · Science · 2014 · 344 · 18910.1126/science.1248024 ↗
42. Giunta · J. Cell Biol. · 2010 · 190 · 19710.1083/jcb.200911156 ↗
43. Rees · Nat. Commun. · 2019 · 10 · 110.1038/s41467-018-07882-8 ↗
44. Boucrot · Proc. Natl. Acad. Sci. U. S. A. · 2007 · 104 · 793910.1073/pnas.0702511104 ↗
45. Walczyk · J. Am. Chem. Soc. · 2010 · 132 · 576110.1021/ja910675v ↗
46. Jiang · Nat. Nanotechnol. · 2008 · 3 · 14510.1038/nnano.2008.30 ↗
47. Liu · Radiother. Oncol. · 2016 · 119 · 54410.1016/j.radonc.2016.04.033 ↗
48. Zhang · Oxid. Med. Cell. Longevity · 2016 · 2016 · 435096510.1155/2016/4350965 ↗
49. Gut · Arch. Toxicol. · 2000 · 74 · 43710.1007/s002040000141 ↗
50. Cao · J. Cell. Biochem. · 2005 · 96 · 81010.1002/jcb.20563 ↗
51. Helleday · Nat. Rev. Cancer · 2008 · 8 · 19310.1038/nrc2342 ↗
52. Banáth · Cancer Res. · 2003 · 63 · 4347
53. Hill · Invest. New Drugs · 1994 · 12 · 16910.1007/BF00873957 ↗